- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02464696
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
A Prospective Randomized Controlled Trial of Early Non-Invasive Positive Pressure Ventilation in Patients With Hypoxemic Respiratory Failure and Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the percent of patients who meet criteria for intubation within 28 days of study inclusion.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A (NIPPV THERAPY): Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
ARM B (HIGH FLOW OXYGEN THERAPY): Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
IDIOPATHIC PULMONARY SYNDROME (IPS) SUBGROUP (INCLUDING DIFFUSE ALVEOLAR HEMORRHAGE): Patients with IPS receive methylprednisolone daily on days 0-48 and every other day (QOD) on days 49-55 in parallel with NIPPV or oxygen therapy, with a taper at the discretion of the treating physician.
After completion of study, patients are followed up until day 100.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nisha Rathi, MD
- Phone Number: 713-792-5040
- Email: NRathi@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Nisha Rathi
- Phone Number: 713-792-5040
- Email: NRathi@mdanderson.org
-
Principal Investigator:
- Nisha Rathi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio =< 300 mmHg OR a peripheral capillary oxygen saturation (SaO2):FiO2 =< 357
- Have a diagnosed malignancy
- Chest radiograph or computed tomography (CT) scan within =< 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
- Probability of survival is at least 6 months
Exclusion Criteria:
- Presence of do not resuscitate (DNR)/do not intubate (DNI) orders at study entry
- Clinical evidence of left heart failure as the main etiology for respiratory compromise
- Evidence of active intrathoracic malignancy (primary or metastatic) in the lungs or pleural space that is a significant cause of respiratory insufficiency
- Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
- Evidence of accessory respiratory muscle use with breathing
- Shock (need for vasopressor therapy or mean arterial pressure [MAP] < 60 despite fluid administration)
- Oliguric acute renal failure (urine output < 500 ml/day) unless already on hemodialysis
- Patient already on NIPPV at the time of screening
- pH < 7.30 or partial pressure of carbon dioxide (pCO2) > 50 (if available)
- Fixed upper airway obstruction
- Airway or facial trauma that would hinder the use of a NIPPV mask
- Uncontrolled tachy or bradyarrhythmia or active myocardial ischemia defined as either: atrial fibrillation with rapid ventricular response (heart rate [HR] > 120 beats per minute [bpm]), ventricular tachycardia or nonsustained ventricular tachycardia (any rate), supraventricular tachycardia (any rate), third degree heart block (any rate), heart rate less than 40 beats per minute (regardless of the rhythm)
- Active myocardial ischemia defined as a clinical presentation at the time of screening consistent with acute coronary syndrome which includes unstable angina and electrocardiogram (EKG) changes suggestive of an either an acute ST elevation myocardial infarction (new ST elevations or new left bundle branch block) or acute non-ST elevation myocardial infarction (new ST depressions, new T wave inversions)
- Glasgow Coma Scale (GCS) < 8 or inadequate airway protective reflexes
- Undrained pneumothorax/pneumomediastinum
- Copious secretions (> 20 cc's of sputum production per hour or significant hemoptysis defined as > 100 cc's of hemoptysis in a 24 hour period
- Risk for gastric aspiration (ie; ileus, esophageal or bowel obstruction, active vomiting)
- Recent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)
- Inability to cooperate with NIPPV
- Refusal to receive NIPPV
- Respiratory arrest
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (NIPPV therapy)
Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
|
IPS cohort only
Other Names:
Undergo NIPPV
|
Active Comparator: Arm B (high flow oxygen therapy)
Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital.
Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
|
IPS cohort only
Other Names:
Receive high flow oxygen therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of patients who require intubation or meet criteria for intubation
Time Frame: Up to 28 days from study inclusion
|
Fisher's exact test or a chi-squared test will be used to assess the association between two categorical variables.
The intubation rate by 28 days and 95% confidence intervals will be estimated for each treatment arm.
Logistic regression will be utilized to assess the effect of patient prognostic factors on the intubation rate by 28 days.
|
Up to 28 days from study inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to intubation
Time Frame: Up to 28 days
|
The Kaplan-Meier method will be used to estimate the time-to-event distribution for each treatment group, and the median time will be provided.
The log-rank test will be used to examine the time-to-event distribution of the active treatment group versus that of the control.
Time to intubation rate at different time points will be provided by treatment group (i.e. at 7 days, 14 days, 21 days, and 28 days).
Since there might be other competing risks for intubation, a competing risk analysis will be performed treating these early events as a competing event for intubation.
|
Up to 28 days
|
Intensive care unit length of stay
Time Frame: Up to 28 days
|
Descriptive statistics, including the mean, standard deviation, median, and range, will be provided.
The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the non-invasive positive pressure ventilation (NIPPV) arm and the control arm.
|
Up to 28 days
|
Hospital length of stay
Time Frame: Up to 28 days
|
Descriptive statistics, including the mean, standard deviation, median, and range, will be provided.
The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the NIPPV arm and the control arm.
|
Up to 28 days
|
Change in partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio
Time Frame: Baseline up to 28 days
|
Descriptive statistics, including the mean, standard deviation, median, and range, will be provided.
The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the NIPPV arm and the control arm.
|
Baseline up to 28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nisha Rathi, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Neoplasms
- Respiratory Insufficiency
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- 2015-0165 (Other Identifier: M D Anderson Cancer Center)
- NCI-2015-01514 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Methylprednisolone
-
Rennes University HospitalUnknownMultiple Sclerosis, Relapsing-RemittingFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Universidad Nacional Autonoma de MexicoInstituto Nacional de Neurología y NeurocirugíaEnrolling by invitationMethylprednisolone | Intranasal Administration | Patients With an Active Multiple Sclerosis RelapseMexico
-
LEO PharmaBayerCompleted
-
Assiut UniversityCompleted
-
Chang Gung Memorial HospitalRecruitingMucocutaneous Lymph Node SyndromeTaiwan
-
Fred LublinPfizer; National Multiple Sclerosis SocietyTerminatedMultiple SclerosisUnited States
-
Peking University People's HospitalBeijing HospitalUnknownImmune Thrombocytopenia
-
University of Colorado, DenverUniversity of Pennsylvania; MallinckrodtTerminatedMultiple SclerosisUnited States
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil